Skip to main content
The Markets by Proactive
Go to Proactive Australia

Archive

Lumos Diagnostics targets key US approvals for FebriDx test - ASX SMIDcaps

Lumos Diagnostics targets key US approvals for FebriDx test - ASX SMIDcaps

Lumos Diagnostics CFO Barrie Lambert joins Proactive's Fouad Haidar live from the ASX Small and Mid Cap Conference. Lumos specialises in rapid, cost-effective and complete point-of-care diagnostic test solutions to help healthcare professionals more accurately diagnose and manage medical conditions.

Lumos offers customised assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures and commercialises proprietary, Lumos-branded point-of-care tests that target infectious and inflammatory diseases.